European & Developing Countries Clinical Trials Partnership

European Union to boost Ebola research with $30.9 million

Thursday, October 23, 2014

The European Commission (E.C.) has announced $30.9 million from the European Union (E.U.) budget for urgently needed Ebola research. The funding will go to five projects, ranging from a large-scale clinical trial of a potential vaccine, to testing existing and novel compounds to treat Ebola. The money from Horizon 2020, an E.U. research and innovation program, will be provided via a fast-track procedure in order to start work as soon as possible. The commission also is working with industry on the further development of vaccines, drugs and diagnostics for Ebola and other haemorrhagic diseases within the Innovative Medicines Initiative.

[Read More]

G-FINDER report: Governments cutting funding for neglected disease R&D

Friday, December 13, 2013

The sixth annual G-FINDER survey reported both good and bad news on global investment into R&D for new neglected disease products. The good news is that global funding for neglected disease R&D totaled $3.2 billion in 2012, thanks to an increase in funding from repeat survey participants of $92.1 million (up 3.2%) over 2011 levels—a positive change as global investment in neglected disease R&D had been declining since 2009. But in 2012, non-U.S. government funding fell by $52.6 million (down 12.4%), with 11 governments cutting or freezing funding. Since the global financial crisis, total investment from this group has fallen by 20% ($90.6 million).

[Read More]